Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension.
We present the case of an HIV/HCV-coinfected patient with HIV-related pulmonary hypertension (HRPH) who experienced a good clinical and functional response to bosentan, with a subsequent switch to oral sildenafil due to increased transaminase levels. Bosentan resulted less handy in this case, probably due to both side effects and co-morbidities.
Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome;
Pierangelo
P
Chinello
Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome;
Stefania
S
Cicalini
U.O. Diagnostica per Immagini, S. Camillo-Forlanini Hospital, Rome;
Andrea
A
Cortese
III Cardiology Unit, S. Camillo-Forlanini Hospital, Rome, Italy.
Maria Paola
MP
Cicini
Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome;
Nicola
N
Petrosillo
HIV; bosentan; pulmonary arterial hypertension.; sildenafil